44 completed, 2 recruiting, 2 terminated, 2 unknown. 18 Phase 3, 15 Phase 4, 11 Phase 2, 8 Phase 1, 1 Not applicable.
Follow Boostrix: new trials by email Literature Review of Boostrix trials Research Report on Boostrix
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women dTpa - Diphtheria-Tetanus-acellular Pertussis Vaccines | Phase 3 | Active not recruiting | GlaxoSmithKline | 102 | 2026-06-29 | 2026-09-08 |
| Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy Tdap Vaccine Administration, RSV Vaccine, Saline (as a placebo) - RSV, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination | Phase 4 | Recruiting | Canadian Immunization Research Network | 60 | 2025-10-16 | 2026-10-22 |
| A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults GC3111B, Boostrix® - Tetanus-diphtheria-acellular Pertussis (Tdap) | Phase 1 / Phase 2 | Recruiting | GC Biopharma Corp | 120 | 2025-06-05 | 2025-07-10 |
| GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age GBS-NN/NN2 vaccine, Tdap vaccine, Placebo - Streptococcus Agalactiae Infection | Phase 2 / Phase 3 | Withdrawn | Minervax ApS | 2024-12-17 | 2026-10-13 | |
| Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults TYP04A Low Dose without Alum investigational vaccine, TYP04B Full Dose without Alum investigational vaccine, TYP03A Low Dose with Alum investigational vaccine - Typhoid Fever | Phase 1 | Completed | GlaxoSmithKline | 97 | 2022-11-28 | 2025-01-24 |
| The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd) Hepatitis A vaccine, Diphtheria, pertussis, and tetanus booster vaccine - Rheumatic Diseases | Phase 4 | Terminated | Oregon Health and Science University | 129 | 2022-10-11 | 2026-09-24 |
| A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose, Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose, Typhoid conjugate vaccine (TCV) low dose - Salmonella Infections | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 155 | 2022-09-13 | 2025-11-28 |
| A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age RSV MAT vaccine, dTpa vaccine - Respiratory Syncytial Virus Infections | Phase 3 | Completed | GlaxoSmithKline | 9 | 2022-02-02 | 2023-04-07 |
| Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children BPZE1 pertussis vaccine and placebo, BPZE1 pertussis vaccine and Boostrix, Placebo and Boostrix - Bordetella Pertussis, Whooping Cough | Phase 2 | Completed | ILiAD Biotechnologies | 368 | 2021-11-11 | 2025-11-06 |
| A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants AltSonflex1-2-3 High Dose, AltSonflex1-2-3 Medium Dose, AltSonflex1-2-3 Low Dose - Diarrhoea | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 551 | 2021-10-06 | 2026-06-22 |
| A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults GC3111 vaccine, Boostrix® vaccine - Tetanus, Diphtheria | Phase 2 | Unknown | Green Cross Corporation | 213 | 2019-10-14 | 2020-01-23 |
| The Safety of Boostrix Following Routine Immunization of Pregnant Women Safety assessment following routine immunization with Boostrix - Whooping Cough | Completed | GlaxoSmithKline | 65783 | 2018-04-13 | 2022-05-18 | |
| Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian Subjects Boostrix - Diphtheria-Tetanus-acellular Pertussis Vaccines | Phase 3 | Completed | GlaxoSmithKline | 448 | 2018-01-26 | 2020-10-27 |
| The Feasibility of Pertussis Immunization in a Canadian Emergency Department Tdap - Pertussis | Not applicable | Completed | University of Prince Edward Island | 644 | 2017-07-10 | 2018-01-26 |
| Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV), Non-Influenza Comparator (Boostrix) - Influenza | Phase 3 | Completed | Seqirus | 6790 | 2016-09-30 | 2020-06-17 |
| Viaskin Pertussis Vaccine Trial Viaskin PT 25 mcg, Viaskin PT 50 mcg, Viaskin PT Placebo - Whooping Cough | Phase 1 | Completed | DBV Technologies | 102 | 2016-09-05 | 2020-03-02 |
| A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults GVGH S. sonnei (1790GAHB) vaccine 25 μg, GVGH S. sonnei (1790GAHB) vaccine 100 μg, Menveo - Shigella Sonnei Infection | Phase 2 | Completed | GlaxoSmithKline | 74 | 2016-08-08 | 2019-02-18 |
| Maternal Tdap Immunization in Guatemala Tdap, Td - Pertussis, Whooping Cough | Phase 2 | Completed | Emory University | 286 | 2016-07-01 | 2019-10-16 |
| Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine Biological: GC3111 vaccine, Biological: Boostrix® vaccine - Tetanus, Diphtheria | Phase 1 / Phase 2 | Unknown | Green Cross Corporation | 220 | 2016-06-01 | 2016-11-07 |
| Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women RSV vaccine GSK3003891A, Boostrix - Respiratory Syncytial Virus Infections | Phase 2 | Completed | GlaxoSmithKline | 102 | 2016-04-01 | 2018-06-26 |
Showing 20 of 52. Sign in to see all of them.
Diphtheria (25) · Tetanus (25) · Whooping Cough (19) · Respiratory Syncytial Virus Infections (3) · Influenza, Human (2) · Meningococcal Infections (2) · Arthritis, Rheumatoid (1) · Diarrhea (1) · Dysentery, Bacillary (1) · Emergencies (1) · Herpes Zoster (1) · Meningitis (1) · Meningitis, Meningococcal (1) · Otitis Media (1) · Otitis Media with Effusion (1)
GlaxoSmithKline (31) · Green Cross Corporation (2) · Universiteit Antwerpen (2) · Canadian Immunization Research Network (1) · DBV Technologies (1) · Eli Lilly and Company (1) · Emory University (1) · GC Biopharma Corp (1) · ILiAD Biotechnologies (1) · Menzies School of Health Research (1) · Minervax ApS (1) · Novartis (1) · Oregon Health and Science University (1) · Public Health England (1) · Sanofi (1)
United States (15) · Belgium (9) · Australia (6) · South Korea (5) · Canada (4) · Czechia (3) · Thailand (3) · China (2) · Dominican Republic (2) · Estonia (2) · Germany (2) · Kenya (2) · Spain (2) · Switzerland (2) · United Kingdom (2)
Aaron Sibley, MD (1) · Amanda J Leach, PhD (1) · Bahaa Abu-Raya, M.D., PhD (1) · Christoph Hatz, Professor (1) · Claire Anne Siegrist, M.D (1) · Edward K Mulholland, DM (1) · Elke Leuridan, MD PhD (1) · Elke Leuridan, MD, PhD (1) · Geert Leroux-Roels, Prof., MD (1) · Jonathan R Carapetis, PhD (1) · Mimi LK Tang, PhD (1)
PMID 29401325, PMID 15882526, PMID 21134450, PMID 21945698, PMID 25613716, PMID 25882172, PMID 26529076, PMID 27142328, PMID 29116597, PMID 29172945, PMID 29789243, PMID 29960800, PMID 30603376, PMID 30877773, PMID 31301919, PMID 31418814, PMID 31443993, PMID 31951765, PMID 32331806, PMID 32896653, PMID 33577767, PMID 35135700, PMID 36211411, PMID 36520325, PMID 37285482, PMID 38752802, PMID 38853614, PMID 39066382, PMID 39385752, PMID 41122946, PMID 41276263, PMID 41587557, PMID 42234814, PMID 42822488
2014 (3), 2015 (3), 2023 (1)